Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ) XVIPY Peers
See (XVIPY) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
---|---|---|---|---|---|---|
XVIPY | $11.45 | -6.53% | 360.67M | N/A | N/A | N/A |
BMXXY | $12.95 | N/A | 15.27B | 32.37 | $0.40 | +0.70% |
EBOSY | $41.94 | N/A | 2.11B | 22.92 | $1.83 | N/A |
EBRCZ | $0.55 | N/A | 203.39M | -4.57 | -$0.12 | N/A |
TRXDW | $0.15 | -11.76% | 40.09M | N/A | N/A | N/A |
NVNBW | $1.00 | N/A | 17.54M | -0.51 | -$1.95 | N/A |
GWPC | $0.00 | N/A | 51950.00 | -0.01 | -$0.01 | N/A |
SXHHF | $0.00 | +0.00% | 38133.00 | -0.01 | -$0.01 | N/A |
KKUR | $0.00 | N/A | 8200.00 | N/A | N/A | N/A |
OMRX | $0.00 | +0.00% | 5321.00 | N/A | -$0.02 | N/A |
Stock Comparison
XVIPY vs BMXXY Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, BMXXY has a market cap of 15.27B. Regarding current trading prices, XVIPY is priced at $11.45, while BMXXY trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas BMXXY's P/E ratio is 32.37. In terms of profitability, XVIPY's ROE is +0.10%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, XVIPY is less volatile compared to BMXXY. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs EBOSY Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, EBOSY has a market cap of 2.11B. Regarding current trading prices, XVIPY is priced at $11.45, while EBOSY trades at $41.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas EBOSY's P/E ratio is 22.92. In terms of profitability, XVIPY's ROE is +0.10%, compared to EBOSY's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to EBOSY. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs EBRCZ Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, EBRCZ has a market cap of 203.39M. Regarding current trading prices, XVIPY is priced at $11.45, while EBRCZ trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas EBRCZ's P/E ratio is -4.57. In terms of profitability, XVIPY's ROE is +0.10%, compared to EBRCZ's ROE of -0.91%. Regarding short-term risk, XVIPY and EBRCZ have similar daily volatility (0.00).
XVIPY vs TRXDW Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, TRXDW has a market cap of 40.09M. Regarding current trading prices, XVIPY is priced at $11.45, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas TRXDW's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to TRXDW's ROE of -4.07%. Regarding short-term risk, XVIPY and TRXDW have similar daily volatility (0.00).
XVIPY vs NVNBW Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, NVNBW has a market cap of 17.54M. Regarding current trading prices, XVIPY is priced at $11.45, while NVNBW trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas NVNBW's P/E ratio is -0.51. In terms of profitability, XVIPY's ROE is +0.10%, compared to NVNBW's ROE of -0.51%. Regarding short-term risk, XVIPY and NVNBW have similar daily volatility (0.00).
XVIPY vs GWPC Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, GWPC has a market cap of 51950.00. Regarding current trading prices, XVIPY is priced at $11.45, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas GWPC's P/E ratio is -0.01. In terms of profitability, XVIPY's ROE is +0.10%, compared to GWPC's ROE of N/A. Regarding short-term risk, XVIPY and GWPC have similar daily volatility (0.00).
XVIPY vs SXHHF Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, SXHHF has a market cap of 38133.00. Regarding current trading prices, XVIPY is priced at $11.45, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, XVIPY's ROE is +0.10%, compared to SXHHF's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to SXHHF. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs KKUR Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, KKUR has a market cap of 8200.00. Regarding current trading prices, XVIPY is priced at $11.45, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas KKUR's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to KKUR's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to KKUR. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs OMRX Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, OMRX has a market cap of 5321.00. Regarding current trading prices, XVIPY is priced at $11.45, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas OMRX's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to OMRX's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to OMRX. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs SCIE Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, SCIE has a market cap of 4924.00. Regarding current trading prices, XVIPY is priced at $11.45, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas SCIE's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to SCIE's ROE of +0.00%. Regarding short-term risk, XVIPY is less volatile compared to SCIE. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs DGCRF Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, DGCRF has a market cap of 4304.00. Regarding current trading prices, XVIPY is priced at $11.45, while DGCRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas DGCRF's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to DGCRF's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to DGCRF. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs IBXG Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, IBXG has a market cap of 1975.00. Regarding current trading prices, XVIPY is priced at $11.45, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas IBXG's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to IBXG's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to IBXG. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs DMSI Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, DMSI has a market cap of 1917.00. Regarding current trading prices, XVIPY is priced at $11.45, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas DMSI's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to DMSI's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to DMSI. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs AAXT Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, AAXT has a market cap of 1599.00. Regarding current trading prices, XVIPY is priced at $11.45, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas AAXT's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, XVIPY and AAXT have similar daily volatility (0.00).
XVIPY vs XCRP Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, XCRP has a market cap of 1516.00. Regarding current trading prices, XVIPY is priced at $11.45, while XCRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas XCRP's P/E ratio is -0.00. In terms of profitability, XVIPY's ROE is +0.10%, compared to XCRP's ROE of -3.49%. Regarding short-term risk, XVIPY is less volatile compared to XCRP. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs BMGP Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, BMGP has a market cap of 1265.00. Regarding current trading prices, XVIPY is priced at $11.45, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas BMGP's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to BMGP's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to BMGP. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs IMRSQ Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, IMRSQ has a market cap of 626.00. Regarding current trading prices, XVIPY is priced at $11.45, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to IMRSQ's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to IMRSQ. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs STBV Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, STBV has a market cap of 472.00. Regarding current trading prices, XVIPY is priced at $11.45, while STBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas STBV's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to STBV's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to STBV. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs OMDD Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, OMDD has a market cap of 310.00. Regarding current trading prices, XVIPY is priced at $11.45, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas OMDD's P/E ratio is N/A. In terms of profitability, XVIPY's ROE is +0.10%, compared to OMDD's ROE of N/A. Regarding short-term risk, XVIPY is less volatile compared to OMDD. This indicates potentially lower risk in terms of short-term price fluctuations for XVIPY.
XVIPY vs QMED Comparison
XVIPY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, XVIPY stands at 360.67M. In comparison, QMED has a market cap of 17.00. Regarding current trading prices, XVIPY is priced at $11.45, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
XVIPY currently has a P/E ratio of N/A, whereas QMED's P/E ratio is -0.00. In terms of profitability, XVIPY's ROE is +0.10%, compared to QMED's ROE of N/A. Regarding short-term risk, XVIPY and QMED have similar daily volatility (0.00).